Viatris agrees to acquire Pacira BioSciences
Story updates
11:45:30 AM UTC
SquawkNews
VTRS PCRX VTRS PCRX - Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
11:45:56 AM UTC
SquawkNews
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
11:46:21 AM UTC
SquawkNews
Viatris to Buy Pacira for $36.50/Shr Cash, Representing an Equity Value of $1.65B >VTRS
11:47:04 AM UTC
SquawkNews
PCRX Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
11:49:45 AM UTC
SquawkNews
Viatris NASDAQ:VTRS said on Thursday it has agreed to acquire Pacira Biosciences NASDAQ:PCRX for $1.65 billion, adding the pain therapy maker's products to its portfolio as it seeks to expand its innovative medicines business.
11:54:53 AM UTC
SquawkNews
* Viatris Agrees To Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy And Becoming A Leader In Non-Opioid Pain Therapies >VTRS PCRX
11:56:31 AM UTC
SquawkNews
Viatris NASDAQ:VTRS said on Thursday it will buy Pacira Biosciences NASDAQ:PCRX for $1.65 billion, adding the pain therapy maker's products to its portfolio.Viatris will pay $36.50 per share in cash, a premium of about 44.8% to Pacira's last closing price.The acquisition is part of Viatris' push to…